BioNTech Targets €500 Million in Annual Cost Savings as Shareholders Endorse Oncology Pivot and Await Pivotal Lung Cancer Data

BioNTech shareholders approve oncology pivot with 92% vote; Q1 net loss €531M as R&D surges. Key Pumitamig data at ASCO in focus.

BioNTech’s transformation from a pandemic vaccine champion to a broad oncology player is proving costly – and shareholders have given management a clear mandate to see it through. At the company’s annual general meeting on Friday, investors holding 92% of the share capital approved a strategic shift that demands hefty upfront spending while revenue from COVID-19 shots continues to dwindle. The stock, meanwhile, remains under pressure, ending the Xetra session at €76.95 – a year-to-date decline of nearly 7% and well below the key 200-day moving average of around €87.

Board expansion brings deep cancer expertise

The virtual meeting saw all agenda items pass comfortably, including the enlargement of the supervisory board from six to eight members. Two seasoned oncology executives, Iris Löw-Friedrich and Susanne Schaffert, join the panel, both bringing extensive experience in clinical development and commercialisation of cancer therapies. Helmut Jeggle takes over as chairman. In parallel, shareholders authorised a new capital increase plan of up to 50% of current share capital, giving management financial flexibility to support the expanding pipeline. The company also operates a multibillion-dollar share buyback programme.

Financial strain deepens as R&D spending surges

The transition is hammering the bottom line. In the first quarter of 2026, revenue dropped to roughly €118 million, compared with nearly €183 million a year earlier, as demand for coronavirus vaccines evaporated. Research and development costs, however, climbed above $650 million, driving a net loss of €531 million. Despite the red ink, management reaffirmed its full-year guidance, underpinned by a vast cash pile: nearly €17 billion sat in the corporate coffers at the end of March.

To ensure the long-term affordability of its cancer research, BioNTech is streamlining production operations. The company plans to achieve annual cost savings of €500 million by 2029. The belt-tightening comes as the market awaits critical clinical milestones that will test the viability of the oncology pivot.

Pumitamig data set to steal the spotlight

All eyes now turn to the American Society of Clinical Oncology (ASCO) annual meeting in Chicago. The embargo on advance abstracts lifts on 21 May, giving investors a first glimpse of the data BioNTech will present. The highlight is the ROSETTA-Lung-02 study: on 29 May, the company will release Phase 2 results for its experimental bispecific antibody, Pumitamig, used in combination with chemotherapy. The trial pits the drug directly against the established standard-of-care, pembrolizumab (Keytruda), in first-line non-small cell lung cancer. A positive outcome would send a powerful signal to the market.

This late-May presentation kicks off a busy news cycle. BioNTech plans seven late-stage data readouts across its oncology pipeline this year, and by year-end it expects to have 15 Phase 3 trials underway. If Pumitamig delivers convincing efficacy, the strategic makeover of the Mainz-based biotech gains a solid clinical foundation.

A brief scientific interlude

In the nearer term, a different spotlight shines on the science behind the company. On Thursday, Nobel laureate Katalin Karikó, whose foundational work enabled the mRNA technology that propelled BioNTech to prominence, delivers a lecture at Johns Hopkins University. While her speech may draw attention to the platform’s scientific roots, investors are far more focused on the imminent oncology data that will determine whether the costly overhaul pays off.